However, a milder virus could still put pressure . Delta period: July 1, 2021December 18, 2021, reflects the time when Delta was the predominant circulating variant; Omicron period: December 19, 2021January 31, 2022, reflects the time when Omicron was the predominant circulating variant. As with previous variants, being vaccinated greatly protects you from severe disease with omicron. 3501 et seq. MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services. Shook, L. L. et al. The stats are for COVID-associated hospitalizations, which may include people for whom COVID-19 was not the primary reason for admission. Implementing strategies that result in the equitable receipt of COVID-19 vaccinations, through building vaccine confidence, raising awareness of the benefits of vaccination, and removing barriers to vaccination access among persons with disproportionately higher hospitalizations rates from COVID-19, including Black adults, is an urgent public health priority. BNT162b2 vaccine effectiveness against omicron in children 5 to 11 years of age. If ethnicity was unknown, non-Hispanic ethnicity was assumed. CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Children born at Kaiser Permanente Northern California from December 15, 2020, through May 31, 2022. Rates cannot be stratified by pregnancy status because the underlying population of pregnant women in the catchment area is unknown. The vaccines have proved highly safe and effective at reducing the risk of severe illness, hospitalization and death. SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Kim, L. et al. J. Med. 386, 15321546 (2022). Anyone you share the following link with will be able to read this content: Sorry, a shareable link is not currently available for this article. 61) indicates a lower risk of hospitalisation with omicron versus delta, averaging over all age groups and vaccination strata. Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. (2021) Omicron is supercharging the COVID vaccine booster debate. Informed consent was waived because this was a data-only study with no direct contact with participants. Author's reply, Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India, Centers for Disease Control and Prevention, MRC Biostatistics Unit COVID-19 Working Group, Cases, hospital admissions, and hospital attendances in those with delta and omicron SARS-CoV-2 variants, between Nov 29, 2021, and Jan 9, 2022, Risk of hospitalisation and mortality for COVID-19 cases with omicron compared with delta, overall and by age group, Estimated HRs for vaccination categories, secondary analysis. During the Omicron-predominant period, peak hospitalization rates among non-Hispanic Black (Black) adults were nearly four times the rate of non-Hispanic White (White) adults and was the highest rate observed among any racial and ethnic group during the pandemic. and statistical significance was assessed at two-sided p0.05. Weekly / March 25, 2022 / 71(12);466473. As a result, the number of total hospitalizations exceeds the sum of unvaccinated adults, adults who received a primary series without a booster or additional dose, and adults who received a primary series with a booster or additional dose. Wkly. and B.F. P.R. In this design, we used Cox proportional hazards models with calendar days as the underlying scale to estimate hazard ratios and calculated vaccine effectiveness as 1 minus the hazard ratio. With wave after wave of SARS-CoV-2 variants, COVID-19 patients filled the worlds' hospitals and morgues because not everybody had access to vaccines or were willing to be vaccinated. Thank you for taking the time to confirm your preferences. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. From Jan 1 to Mar 16, 2022, when Omicron was predominant, 4,781 (0.02%) of 19,473,570 booster recipients died of COVID-19, and 58,020 (0.3%) died of other causes. provided as a service to MMWR readers and do not constitute or imply J. Obstet. Polack, F. P. et al. . Starting the week ending December 4, 2021, Maryland data are not included in weekly rate calculations but are included in previous weeks. Kharbanda, E. O. et al. https://www.cdc.gov/nchs/nvss/bridged_race.htm, ** https://www.medrxiv.org/content/10.1101/2021.08.27.21262356v1, On August 13, 2021, CDCs Advisory Committee on Immunization Practices (ACIP) issued the first of several recommendations for additional or booster doses of COVID-19 vaccine. TN and NMF validated the data. Several conditions, including cancer of the blood or bone marrow and dementia, were associated with HRs greater than 3. Wkly. Two recent papers claim there are no differences between surgical masks and respirators for preventing the spread of respiratory diseases like COVID-19 and flu, but the articles are deeply flawed. While Omicron caused a big spike in COVID-19 cases, vaccinated people continued to be less likely to be hospitalized than the unvaccinated. We did not have genotyping data to confirm the variant that infected infants who tested positive and instead relied on state data regarding circulating strain predominance in the Northern California region. ** Monthly incidence among adults who received booster or additional doses was calculated by summing the total number of COVID-19 patients with booster or additional doses hospitalized over all days of the month and dividing by the sum of adults with booster or additional doses in the underlying population for each day of the month. This method was also used for calculations in unvaccinated persons and those who received a primary series but not a booster or additional dose.. Thus, this design better adjusts for healthcare-seeking behavior31,32, but it may also introduce other biases including selection bias33. Christopher A. Taylor, PhD1; Michael Whitaker, MPH1; Onika Anglin, MPH1,2; Jennifer Milucky, MSPH1; Kadam Patel, MPH1,2; Huong Pham, MPH1; Shua J. Chai, MD3,4; Nisha B. Alden, MPH5; Kimberly Yousey-Hindes, MPH6; Evan J. Anderson, MD7,8,9; Kenzie Teno, MPH10; Libby Reeg, MPH11; Kathryn Como-Sabetti, MPH12; Molly Bleecker, MA13; Grant Barney, MPH14; Nancy M. Bennett, MD15; Laurie M. Billing, MPH16; Melissa Sutton, MD17; H. Keipp Talbot, MD18; Keegan McCaffrey19; Fiona P. Havers, MD1; COVID-NET Surveillance Team (View author affiliations). Compared with the Delta-predominant period, the proportion of unvaccinated hospitalized Black adults increased during the Omicron-predominant period. Mortal. Razzaghi, H. et al. 45 C.F.R. Dr. Klein reported receiving grants from Pfizer, Merck, GlaxoSmithKline, and Sanofi Pasteur. https://doi.org . N. Engl. Maryland did not contribute data after December 4, 2021, but did contribute data for previous weeks. These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. Sect. 384, 14121423 (2021). Association of COVID-19 vaccination during pregnancy with incidence of SARS-CoV-2 infection in infants. Mortal. The results were unchanged when no adjustments for covariates were made (Supplemental Table3). This analysis describes weekly hospitalization rates during Delta- and Omicron-predominant periods. NMF, SB, SFunk, ACG, DDA, and AMP acquired funding. https://medrxiv.org/cgi/content/short/2021.08.27.21262356v1. volume14, Articlenumber:894 (2023) 552a; 44 U.S.C. And in a second large study during the Omicron period, older people, men, and residents of nursing homes or in low-income areas were most at risk for post-booster COVID-19 death in England, but the risk was very low. Ousseny Zerbo. * Information on the impact that booster or additional doses of COVID-19 vaccines have on preventing hospitalizations during Omicron predominance is limited. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 yearsVISION Network, 10 states, April 2021-January 2022. The average death rate among Americans over age 65 who contract the flu has ranged between 1 in 75 and 1 in 160 in recent years, according to the C.D.C. N. Engl. Symptoms are abstracted from the medical chart and might not be complete. Without the vaccines many more people would likely be in hospital. In this analysis, vaccine effectiveness was evaluated as 1 minus the odds ratio. CDC is not responsible for the content If the SARS-CoV-2 test date was not available, hospital admission date was used. Real-world data suggest lower COVID-19 vaccine effectiveness against Omicron variants11,12,13,14. Vaccine 40, 656665 (2022). Requests for access to the underlying source data should be directed to UKHSA. Two to 4 weeks after a booster dose, vaccine effectiveness ranged from around 65-75%, dropped to 55-70% at 5 to 9 weeks, and 40-50% from 10 weeks or more after a booster dose. Thank you for visiting nature.com. Wkly Rep. 71, 352358 (2022). Although hospitalization rates increased for all adults, rates were highest among unvaccinated adults and lowest among adults who had received a primary series and a booster or additional dose. However, protection estimates greater than 90% might be too high if individuals with a previous infection were more likely than those without one to come forward for a test for reasons other than suspicion of COVID-19. J. Our primary cohort analysis used calendar days as the underlying scale to ensure that we compared infants of vaccinated and unvaccinated mothers on the same calendar days because vaccination status during pregnancy and risk of SARS-CoV-2 infection varied over the study period. Surveillance officers abstracted data on sampled patients from medical charts. Relative to the Delta-predominant period, a larger proportion of hospitalized Black adults were unvaccinated. Saving Lives, Protecting People, https://covid.cdc.gov/covid-data-tracker/#variant-proportions, https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covid-net/purpose-methods.html, https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e3.htm, https://www.cdc.gov/nchs/nvss/bridged_race.htm, https://www.medrxiv.org/content/10.1101/2021.08.27.21262356v1, https://www.cdc.gov/mmwr/volumes/70/wr/mm7050e2.htm, https://www.nejm.org/doi/full/10.1056/NEJMoa2114255, https://medrxiv.org/cgi/content/short/2021.08.27.21262356v1, https://www.medrxiv.org/content/10.1101/2022.01.11.22269045v1, https://data.cdc.gov/Vaccinations/COVID-19-Vaccination-Demographics-in-the-United-St/km4m-vcsb, https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html, https://doi.org/10.1001/jamanetworkopen.2021.30479, Centers for Disease Control and Prevention, U.S. Department of Health & Human Services, American Indian or Alaska Native, non-Hispanic, Psychiatric admission requiring medical care. These findings are consistent with the diminishing of pregnancy-derived antibodies in infants over time22. "The association between the QCovid risk groups and the risk of death were stronger in people who had received a booster and were infected by the Omicron variant compared with evidence from the Alpha and Delta period in doubly vaccinated individuals," the authors wrote. Fully-vaccinated in this chart meant one dose of the J&J vaccine or two doses of Pfizer or Moderna. Google Scholar. 387, 227236 (2022). Maternal vaccination and risk of hospitalization for Covid-19 among infants. The findings in this report are subject to at least four limitations. Spontaneous abortion following COVID-19 vaccination during pregnancy. After adjusting for covariates, vaccination during pregnancy significantly reduced the risk of the infant testing SARS-CoV-2 positive by 84% (95% confidence interval [CI]: 66, 93) during the first 2 months of life, 62% (95% CI: 39, 77) during the first 4 months of life and 56% (95% CI: 34,71) during the first 6 months of life. Rep. 71, 2630 (2022). Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of PubMed JAMA Netw. Adults who received booster doses were classified as those who completed the primary series and received an additional or booster dose on or after August 13, 2021, at any time after completion of the primary series, and 14 days before a positive test result for SARS-CoV-2, as COVID-19associated hospitalizations are a lagging indicator and time passed after receipt of a booster dose has been shown to be associated with reduced rates of COVID-19 infection (https://www.nejm.org/doi/full/10.1056/NEJMoa2114255). Get the most important science stories of the day, free in your inbox. *** LTCF residents include hospitalized adults who were identified as residents of a nursing home/skilled nursing facility, rehabilitation facility, assisted living/residential care, long-term acute care hospital, group/retirement home, or other LTCF upon hospital admission. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. When possible, CDC associates a persons primary vaccination series and booster dose with that person. T.R. Vaccination status is based on state immunization information system data. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Morb. Clinical information was abstracted for 5,681 adults with COVID-19associated hospitalization during July 1, 2021January 31, 2022 (Table). Morb. J. Med. The second study, led by Office for National Statistics researchers in Wales, involved death rates and risk factors in adults in England who had received an mRNA booster at least 14 days before Dec 31, 2021. New charts from the Centers for Disease Control and Prevention (CDC) showed that hospitalization rates were much lower among those who were vaccinated even as Omicron was sweeping the nation. Internet Explorer). Am. Kaiser Permanente Northern California, Vaccine Study Center, Oakland, CA, USA, Ousseny Zerbo,G. Thomas Ray,Bruce Fireman,Evan Layefsky,Kristin Goddard,Edwin Lewis,Pat Ross&Nicola P. Klein, Yale University, Institute for Global Health, New Haven, CT, USA, Department of Internal Medicine (Infectious Diseases), Yale School of Medicine, New Haven, CT, USA, Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA, Obstetrics and Gynecology, Kaiser Permanente Northern California Oakland, Oakland, CA, USA, Regional Perinatal Service Center, Kaiser Permanente Northern California, Santa Clara, CA, USA, You can also search for this author in adjudicated chart reviews. TN and NMF were responsible for visualisation. In this primary design, all eligible infants meeting inclusion criteria were included without sampling which improved power and minimized bias related to selection. Furthermore, it was reassuring that both the cohort and the secondary TND yielded vaccine effectiveness estimates in the same direction. The outcomes were the infants first positive nasal/throat swab for SARS-CoV-2 by PCR, and the first COVID-19-related hospitalization, occurring during the first 6 months of life and recorded in the electronic health record. The study was funded by the National Institute of Allergy and Infectious Disease grant # 1R01AI168373-01 to O.Z. Foppa, I. M., Haber, M., Ferdinands, J. M. & Shay, D. K. The case test-negative design for studies of the effectiveness of influenza vaccine. In this large study which included >30,000 infants, we found that receipt of at least two doses of mRNA COVID-19 vaccine during pregnancy was associated with a decreased risk of infants testing SARS-CoV-2 positive during their first 6 months of life. 226, 236 e1236.e14 (2022). During the Delta period, receipt of one dose during the third trimester reduced infants risk of testing positive for SARS-CoV-2 by 74% (95% CI: 19, 92) during the first 6 months of life (Table3). If SARS-CoV-2 test date was missing, hospitalization admission date was used. Data about boosters was only available for those over 50. TN, NMF, SGN, DDA, AMP, and ST wrote the original draft of the manuscript. TN, NMF, SFlax, SFunk, SA, SB, and ST did the formal analysis. However, data currently available on the persistence of immunity after vaccination on the one hand and the emergence of viral variants with reduced sensibility to vaccine immunity on the other, raise the need to administer boosters to maintain the protection and to compare .